From Medscape Diabetes & Endocrinology

Coverage from the

American Society for Bone and Mineral Research (ASBMR) 2018 Annual Meeting

September 28 - October 01, 2018; Montreal, Quebec

September 28 - October 01, 2018 Montreal, Quebec

ASBMR 2018 Can Rare Rebound Fractures After Denosumab Therapy Be Avoided? Two studies suggest rare rebound vertebral fractures after stopping denosumab may be averted by giving a potent bisphosphonate and not continuing aromatase inhibitors beyond 6 months of stopping.
Medscape Medical News, October 22, 2018
ASBMR 2018 Are Osteoporosis Drugs Linked With Survival? Debate Casts Doubt The mortality benefit of osteoporosis drugs is "probably around 10%," claims one expert. However, strong evidence to support prescribing these drugs for this reason "is just not there," says another.
Medscape Medical News, October 11, 2018
ASBMR 2018 Secondary Fracture Risk Stays High, Early Risk Is Greater in Men 'These results underscore the importance of timely recognition of fracture events, especially in men,' says the lead author of a 25-year case-control study.
Medscape Medical News, October 8, 2018

Conference News

ASBMR 2018 Can Rare Rebound Fractures After Denosumab Therapy Be Avoided?
Medscape Medical News, October 22, 2018
ASBMR 2018 Are Osteoporosis Drugs Linked With Survival? Debate Casts Doubt
Medscape Medical News, October 11, 2018
ASBMR 2018 Secondary Fracture Risk Stays High, Early Risk Is Greater in Men
Medscape Medical News, October 8, 2018
ASBMR 2018 Zoledronate Reduces Fractures in Older Women With Osteopenia
Medscape Medical News, October 4, 2018

ASBMR 2018 Study Finds BMD Can Stand in for Fractures. Will the FDA Agree?
Medscape Medical News, October 3, 2018
ASBMR 2018 ASBMR Urges Bone Treatment for All Seniors With Major Fractures
Medscape Medical News, October 1, 2018
ASBMR 2018 Beyond 2 Years, Bisphosphonate Holiday Ups Broken Hip Risk
Medscape Medical News, October 1, 2018
ASBMR 2018 ASBMR 2018 to Tackle 'Problems Bone Doctors Struggle With'
Medscape Medical News, September 27, 2018

Popular News from ASBMR 2017

Romosozumab in ARCH: Good Fracture Reduction, but CV Effects a Worry Results from the ARCH trial are encouraging for the anabolic drug, but experts' voice concern over cardiovascular events; for now, the drug is in regulatory limbo.
Medscape Medical News, Sep 13, 2017
Long-term PTH Linked to Bone Improvements in Hypoparathyroidism Skeletal improvements are seen after 8 to 10 years of treatment; other research shows quality-of-life improvements.
Medscape Medical News, Sep 20, 2017
Extended DXA, Risk Factors, Predict AFF With Bisphosphonate Use Two new studies indicate novel ways to help identify or predict the small percentage of osteoporosis patients using bisphosphonates who will be adversely affected by atypical femoral fractures.
Medscape Medical News, Sep 11, 2017

Medscape Diabetes© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Previous Coverage

ASBMR 2017